Klinik und Poliklinik für Innere Medizin II, Universitätsklinikum Regensburg, Regensburg, Germany.
Clin Chem Lab Med. 2010 Jun;48(6):875-81. doi: 10.1515/CCLM.2010.164.
Whereas N-terminal pro-brain natriuretic peptide (NT-proBNP) is approved for risk stratification of patients with acute coronary syndromes (ACS), short-term temporal changes in NT-proBNP concentrations and the optimal time points for sampling are not clear. The purpose of this study was to better define the short-term changes in NT-proBNP in relation to clinical presentation, reperfusion and prognostic value in patients with ACS, as well as to identify the optimum time points for sampling.
We studied daily plasma concentrations of NT-proBNP in 133 unselected patients with myocardial infarction (n=65), stable coronary artery disease (CAD, n=46) and no CAD (n=22) who underwent coronary angiography.
Patients with non-ST-elevation myocardial infarction (NSTEMI) presented with markedly higher NT-proBNP than patients with ST-elevation myocardial infarction (STEMI) [1305 (741-3208) ng/L vs. 170 (70-424) ng/L, p<0.001]. Also, time to presentation from onset of pain was much longer in NSTEMI as compared to STEMI (>48 h vs. <6 h, p<0.001). Patients with NSTEMI also presented with higher NT-proBNP as compared with CAD [224 (98-732) ng/L] and no CAD [47 (26-102) ng/L; p<0.001, NSTEMI vs. both]. Following successful percutaneous coronary intervention [thrombolysis in myocardial infarction (TIMI) 3-flow established], NT-proBNP increased markedly within 24 h in patients with STEMI [718 (379-1338) ng/L, p<0.01 vs. 0 h], whereas no change in NT-proBNP was noted in patients with NSTEMI [1190 (1010-2024) ng/L, p=0.88 vs. 0 h]. In both STEMI and NSTEMI, NT-proBNP decreased significantly 96 h after successful reperfusion [STEMI -52%, 372 (189-610) ng/L, p<0.05; NSTEMI -52%, 613 (365-724) ng/L, p<0.05]. Unsuccessful reperfusion (TIMI<3) was associated with unchanged or increased NT-proBNP. NT-proBNP at 96 h and peak NT-proBNP further displayed a strong correlation with cardiac troponin T (r=0.64 and r=0.54, p<0.001), a marker of infarct size, and NT-proBNP at 96 h was a strong predictor of long-term prognosis (hazard ratio 7.29, p=0.025).
In patients with NSTEMI, NT-proBNP may be increased as high as concentrations usually associated with acute congestive heart failure despite the absence of clinical signs. In contrast, patients with STEMI and short time to presentation may present with completely normal NT-proBNP, but dramatic short-term increases following reperfusion. NT-proBNP reflects ischemic burden, reperfusion success and prognosis, and the current data support repetitive sampling in patients with ACS.
尽管 N 端脑利钠肽前体(NT-proBNP)已被批准用于急性冠脉综合征(ACS)患者的风险分层,但 NT-proBNP 浓度的短期变化及其最佳采样时间点尚不清楚。本研究旨在更好地定义 ACS 患者 NT-proBNP 的短期变化与临床表现、再灌注和预后价值之间的关系,并确定最佳采样时间点。
我们研究了 133 例未经选择的心肌梗死(n=65)、稳定型冠状动脉疾病(CAD,n=46)和无 CAD(n=22)患者的每日血浆 NT-proBNP 浓度,这些患者均接受了冠状动脉造影。
非 ST 段抬高型心肌梗死(NSTEMI)患者的 NT-proBNP 明显高于 ST 段抬高型心肌梗死(STEMI)患者[1305(741-3208)ng/L 比 170(70-424)ng/L,p<0.001]。此外,与 STEMI 相比,NSTEMI 患者从疼痛发作到就诊的时间要长得多(>48 h 比<6 h,p<0.001)。与 CAD [224(98-732)ng/L]和无 CAD [47(26-102)ng/L]相比,NSTEMI 患者的 NT-proBNP 也更高(p<0.001,NSTEMI 比两者)。经皮冠状动脉介入治疗成功(心肌梗死溶栓治疗 [TIMI] 3 级血流建立)后,STEMI 患者的 NT-proBNP 在 24 小时内明显升高[718(379-1338)ng/L,p<0.01 比 0 h],而 NSTEMI 患者的 NT-proBNP 无变化[1190(1010-2024)ng/L,p=0.88 比 0 h]。在 STEMI 和 NSTEMI 中,成功再灌注 96 小时后 NT-proBNP 显著下降[STEMI -52%,372(189-610)ng/L,p<0.05;NSTEMI -52%,613(365-724)ng/L,p<0.05]。再灌注失败(TIMI<3)与 NT-proBNP 不变或增加有关。96 小时时的 NT-proBNP 和峰值 NT-proBNP 与心肌肌钙蛋白 T(r=0.64 和 r=0.54,p<0.001)进一步显示出强烈的相关性,心肌肌钙蛋白 T 是心肌梗死面积的标志物,96 小时时的 NT-proBNP 是长期预后的强烈预测因素(风险比 7.29,p=0.025)。
在 NSTEMI 患者中,尽管没有临床症状,NT-proBNP 可能会升高到通常与急性充血性心力衰竭相关的水平。相比之下,STEMI 患者和就诊时间较短的患者可能表现出完全正常的 NT-proBNP,但再灌注后会出现明显的短期增加。NT-proBNP 反映了缺血负担、再灌注成功和预后,当前的数据支持对 ACS 患者进行重复采样。